# Literature Synthesis: PFAS Exposure and Biological Aging

## Executive Summary

This literature synthesis consolidates evidence from 45+ peer-reviewed studies examining the relationship between per- and polyfluoroalkyl substances (PFAS) exposure and biological aging. The synthesis reveals converging evidence from epidemiological, mechanistic, and clinical studies supporting an association between PFAS exposure and accelerated biological aging, as measured by biomarkers including PhenoAge.

---

## 1. Conceptual Framework

### 1.1 Biological Aging vs. Chronological Aging

Biological aging refers to the progressive deterioration of physiological function and increased vulnerability to disease that occurs over time. Unlike chronological aging (simply time elapsed since birth), biological aging captures individual variation in the rate of physiological decline. This variation explains why individuals of the same chronological age can have markedly different disease risks, functional capacities, and lifespans.

**Key Insight**: Environmental exposures, including PFAS, may accelerate biological aging beyond what would be expected based on chronological age alone.

### 1.2 PFAS as Environmental Stressors

PFAS represent a class of synthetic chemicals characterized by:
- **Persistence**: Resistant to environmental degradation
- **Bioaccumulation**: Accumulate in human tissues over time
- **Ubiquity**: Detected in >95% of U.S. adults
- **Biological activity**: Interact with multiple physiological systems

These properties make PFAS ideal candidates for studying environmental contributions to biological aging.

---

## 2. Epidemiological Evidence

### 2.1 Direct PFAS-Biological Aging Associations

**Primary Evidence**: Yan et al. (2025) provides the first direct epidemiological evidence linking PFAS to biological aging acceleration in NHANES.

| PFAS Compound | KDM-BA Association | PhenoAge Association |
|--------------|-------------------|---------------------|
| PFHxS | β=0.56 (0.25-0.87) | β=0.46 (0.08-0.83) |
| PFAS Mixture | β=1.25 (1.04-1.45) | β=0.79 (0.55-1.03) |

*Table 1: PFAS associations with biological aging measures (adapted from Yan et al., 2025)*

**Key Finding**: Mixture effects exceed individual compound effects, highlighting the importance of considering total PFAS burden.

### 2.2 PFAS and Age-Related Disease Spectrum

The literature documents PFAS associations across multiple age-related conditions:

**Cardiovascular System**:
- Coronary heart disease (Mao et al., 2024)
- Dyslipidemia (Wang et al., 2025; Bhagavathula et al., 2025)
- Hypertension components (Boafo et al., 2023)

**Renal System**:
- Chronic kidney disease (Adetunji & Obeng-Gyasi, 2025)
- Reduced eGFR (Haruna & Obeng-Gyasi, 2024)
- Kidney dysfunction (Rahman et al., 2025)

**Metabolic System**:
- Metabolic syndrome (Wan et al., 2024)
- Type 2 diabetes risk
- Obesity (Khalil et al., 2015)

**Sensory Systems**:
- Age-related macular degeneration (Kang et al., 2024)

**Cancer**:
- Multiple cancer types (Mak et al., 2023)

### 2.3 Pattern Recognition

Several patterns emerge across studies:

1. **Non-monotonic dose-responses**: Some studies show inverted U-shaped associations (Kang et al., 2024)
2. **Sex differences**: Postmenopausal women show heightened vulnerability
3. **Age interactions**: Effects often stronger in older adults
4. **Temporal trends**: Legacy PFAS (PFOA, PFOS) declining; emerging PFAS understudied

---

## 3. PhenoAge as an Outcome Measure

### 3.1 Construct Validity

PhenoAge (Levine et al., 2018) represents a clinical biomarker-based measure of biological aging with established validity:

**Predictive Validity**:
- All-cause mortality prediction
- Cancer incidence
- Cardiovascular events
- Physical function decline
- Cognitive impairment

**Construct Validity**:
- Correlates with other aging measures (Belsky et al., 2017)
- Captures physiological dysregulation
- Responsive to environmental exposures

### 3.2 PhenoAge Components

| Biomarker | Direction of Association with Aging | Biological Significance |
|-----------|------------------------------------|------------------------|
| Albumin | Decreased | Nutritional status, inflammation |
| Creatinine | Increased | Kidney function |
| Glucose | Increased | Metabolic dysfunction |
| CRP | Increased | Inflammation |
| Lymphocytes | Decreased | Immune function |
| MCV | Increased | Erythrocyte aging |
| RDW | Increased | Erythrocyte heterogeneity |
| ALP | Increased | Liver/bone metabolism |
| WBC | Increased | Immune activation |

*Table 2: PhenoAge biomarker components and their biological interpretations*

### 3.3 Advantage for PFAS Research

PhenoAge offers several advantages for studying PFAS effects:
- **Comprehensive**: Captures multiple physiological systems
- **Validated**: Strong predictive performance
- **Measurable**: Uses standard clinical laboratory tests
- **Available**: Can be calculated from NHANES data

---

## 4. Mechanistic Pathways

### 4.1 Oxidative Stress and Mitochondrial Dysfunction

**Central Hypothesis**: PFAS-induced oxidative stress accelerates biological aging through mitochondrial damage.

**Evidence**:
- PFAS increase ROS production (Tancreda et al., 2025)
- Mitochondrial membrane potential disruption
- Impaired oxidative phosphorylation (Xu et al., 2025)
- mtDNA damage accumulation

**Relevance to PhenoAge**: 
- Elevated glucose (metabolic stress)
- Increased CRP (oxidative stress marker)
- Altered RBC parameters (oxidative damage to erythrocytes)

### 4.2 Inflammation and Immune Dysregulation

**Central Hypothesis**: Chronic low-grade inflammation mediates PFAS-aging associations.

**Evidence**:
- TLR4 activation by PFAS (Mao et al., 2024)
- NF-κB pathway activation
- Cytokine dysregulation (IL-6, TNF-α)
- Inflammasome activation

**Relevance to PhenoAge**:
- Elevated CRP (acute phase reactant)
- Altered WBC and lymphocytes (immune markers)

### 4.3 Endocrine Disruption

**Central Hypothesis**: PFAS interfere with hormonal systems regulating aging.

**Evidence**:
- Thyroid hormone disruption
- Sex steroid alterations (Wu et al., 2024)
- Klotho suppression (Li et al., 2023)
- Insulin resistance

**Relevance to PhenoAge**:
- Glucose elevation (insulin resistance)
- Albumin changes (nutritional/hormonal status)

### 4.4 Emerging Mechanisms

**Ferroptosis**: Iron-dependent cell death driven by lipid peroxidation (Mazhar et al., 2021)
- PFAS may trigger ferroptosis through oxidative stress
- Represents novel therapeutic target

**Epigenetic Modifications**: 
- DNA methylation changes (Niemiec et al., 2023)
- Histone modifications
- Non-coding RNA alterations

### 4.5 Integrated Mechanistic Model

```
PFAS Exposure
     ↓
Mitochondrial Dysfunction ←→ Oxidative Stress
     ↓                           ↓
Inflammation ←─────────────→ Cellular Damage
     ↓                           ↓
Endocrine Disruption ←─────→ Epigenetic Changes
     ↓                           ↓
     └────→ Biological Aging Acceleration ───→ Disease/Mortality
```

*Figure 1: Conceptual model integrating PFAS mechanisms leading to accelerated biological aging*

---

## 5. Life Course Perspective

### 5.1 Developmental Windows of Susceptibility

**Prenatal Period**:
- PFAS cross placental barrier (Khan et al., 2025)
- Epigenetic programming (Niemiec et al., 2023)
- Organ development disruption

**Childhood/Adolescence**:
- Growth and development effects
- Bone density impacts (Blomberg et al., 2022)
- Pubertal timing

**Adulthood**:
- Cumulative exposure effects
- Age-related vulnerability
- Menopausal transition (women)

### 5.2 Cumulative Exposure Framework

Biological aging represents the cumulative result of:
- Exposure duration
- Exposure intensity
- Exposure timing (critical windows)
- Individual susceptibility factors

**Implication**: Current PFAS levels may underestimate lifetime exposure effects.

---

## 6. Mixture Effects and Complex Exposures

### 6.1 Beyond Single-Chemical Approaches

Traditional risk assessment evaluates chemicals individually, but real-world exposures involve complex mixtures. PFAS literature demonstrates:

- **Additive effects**: Individual contributions sum together
- **Synergistic effects**: Combined impact exceeds sum
- **Interaction effects**: Chemicals modify each other's toxicity

### 6.2 Statistical Methods for Mixtures

**Weighted Quantile Sum (WQS) Regression**:
- Identifies dominant contributors
- Estimates overall mixture effect
- Useful for risk prioritization

**Bayesian Kernel Machine Regression (BKMR)**:
- Captures non-linear relationships
- Evaluates interactions
- Provides variable importance metrics

**Quantile G-Computation**:
- Directional effect estimation
- Intervention simulation
- Policy-relevant outputs

### 6.3 Co-Exposure Considerations

PFAS rarely occur in isolation. Co-exposures include:
- Heavy metals (Pb, Cd, Hg)
- Phthalates
- Brominated flame retardants
- Other persistent organic pollutants

**Finding**: Co-exposures often amplify health effects (Boafo et al., 2023; Odediran et al., 2025).

---

## 7. Vulnerable Populations

### 7.1 Demographic Factors

**Sex/Gender**:
- Women: Higher PFAS during reproductive years (menstrual cycling)
- Postmenopausal women: Reduced excretion, accumulation
- Men: Higher occupational exposures in certain industries

**Age**:
- Older adults: Reduced renal clearance, longer half-lives
- Children: Developmental vulnerability, different exposure sources

**Race/Ethnicity**:
- Differential exposure patterns
- Socioeconomic confounding
- Genetic susceptibility variation

### 7.2 Socioeconomic Status

Lower SES associated with:
- Higher PFAS exposure (environmental justice)
- Reduced resources for risk mitigation
- Higher baseline disease risk
- Reduced healthcare access

### 7.3 Health Status

**Kidney Disease**: Impaired PFAS clearance → higher body burden
**Liver Disease**: Altered PFAS metabolism
**Metabolic Syndrome**: Potential bidirectional relationships

---

## 8. Modifying and Protective Factors

### 8.1 Dietary Factors

**Protective**:
- Caffeine intake (Yan et al., 2025)
- Antioxidant-rich foods
- Fiber (gut microbiome effects)

**Risk Enhancing**:
- High-fat diet (may increase PFAS absorption)
- Processed foods (PFAS packaging)

### 8.2 Lifestyle Factors

**Physical Activity**: May reduce PFAS-related COPD risk (Pan et al., 2024)
**Sleep**: Associated with Klotho levels (Mochón-Benguigui et al., 2020)
**Smoking**: Interacts with PFAS effects

### 8.3 Interventional Opportunities

Findings suggest potential interventions:
- Dietary modifications
- Targeted supplementation
- Lifestyle changes
- Reduced exposure (primary prevention)

---

## 9. Methodological Considerations

### 9.1 Study Design Strengths and Limitations

**Strengths in Current Literature**:
- Large sample sizes (NHANES representative)
- Standardized exposure assessment
- Validated outcome measures
- Advanced statistical methods

**Limitations**:
- Cross-sectional designs (temporality)
- Single time-point exposure measurement
- Residual confounding
- Selection bias (subsample analyses)

### 9.2 Exposure Assessment

**Biomonitoring**: Serum concentrations reflect body burden
- Advantages: Integrates multiple exposure routes
- Limitations: Single time-point, short half-lives for some PFAS

**Temporal Trends**: Legacy PFAS declining, emerging PFAS rising
- Research lag for new compounds
- Mixture composition changing over time

### 9.3 Outcome Assessment

**PhenoAge Advantages**:
- Objective biomarker-based
- Strong predictive validity
- Captures multisystem dysfunction

**Considerations**:
- Individual biomarkers may have different PFAS sensitivities
- Clinical thresholds vs. continuous measures
- Population-specific calibration

---

## 10. Research Gaps and Future Directions

### 10.1 Critical Knowledge Gaps

1. **Causality**: Most evidence cross-sectional; longitudinal cohorts needed
2. **Thresholds**: Non-monotonic dose-responses complicate risk assessment
3. **Mechanisms**: Direct causal pathways remain incompletely characterized
4. **Interventions**: Limited evidence on mitigating strategies
5. **Emerging PFAS**: Newer compounds understudied

### 10.2 Methodological Priorities

1. **Longitudinal Designs**: Track exposure-aging relationships over time
2. **Multi-Omics Integration**: Genomics, epigenomics, metabolomics, proteomics
3. **Causal Inference Methods**: Mendelian randomization, g-computation
4. **Complex Mixtures**: Advanced statistical methods for real-world exposures
5. **Life Course Approaches**: Early-life exposure effects on later-life aging

### 10.3 Translation Priorities

1. **Risk Assessment**: Incorporate mixture effects and vulnerable populations
2. **Regulatory Policy**: Consider cumulative impacts
3. **Clinical Practice**: Screen high-risk populations
4. **Public Health**: Exposure reduction strategies

---

## 11. Implications for Current Study

### 11.1 Hypothesis Support

The literature strongly supports the hypothesis that PFAS exposure is associated with accelerated biological aging:

✓ **Direct evidence**: Yan et al. (2025) demonstrates PFAS-PhenoAge association
✓ **Mechanistic plausibility**: Multiple pathways identified
✓ **Outcome validity**: PhenoAge well-validated as aging measure
✓ **Data availability**: NHANES includes both PFAS and PhenoAge components

### 11.2 Analytical Approach

Recommended approaches based on literature:

1. **Individual PFAS**: Examine PFOA, PFOS, PFHxS, PFNA separately
2. **Mixture Analysis**: Apply WQS, BKMR, or Q-gcomp
3. **Effect Modification**: Test sex, age, race/ethnicity interactions
4. **Sensitivity Analyses**: Address confounding, outliers
5. **Mediation Analysis**: Explore mechanistic pathways if data permit

### 11.3 Expected Findings

Based on literature synthesis, we expect:
- Positive association between PFAS and PhenoAge
- Mixture effects > individual effects
- Heterogeneity by sex and age
- Possible non-linear relationships
- Consistency with KDM-BA (convergent validity)

---

## 12. Conclusions

This literature synthesis reveals converging evidence that PFAS exposure is associated with accelerated biological aging. Key conclusions include:

1. **Epidemiological Evidence**: Direct association demonstrated in NHANES (Yan et al., 2025), supported by multiple studies linking PFAS to age-related diseases

2. **Mechanistic Plausibility**: Oxidative stress, inflammation, mitochondrial dysfunction, and endocrine disruption provide biological mechanisms

3. **Outcome Validity**: PhenoAge is a well-validated measure of biological aging suitable for studying environmental exposures

4. **Mixture Effects**: Real-world PFAS exposures involve complex mixtures with combined effects exceeding individual compound effects

5. **Vulnerable Populations**: Certain groups (postmenopausal women, older adults, lower SES) may be disproportionately affected

6. **Modifiability**: Protective factors (caffeine, antioxidants, physical activity) may mitigate adverse effects

7. **Research Needs**: Longitudinal studies, mechanistic investigations, and intervention research remain priorities

The current study contributes to this evidence base by examining the PFAS-PhenoAge association with rigorous methods in a nationally representative sample. Findings will inform both scientific understanding and public health approaches to addressing PFAS-related health risks.

---

## References

See `references.bib` for complete citations with DOIs.

Key references cited in this synthesis:
- Yan et al., 2025 (direct PFAS-aging evidence)
- Levine et al., 2018 (PhenoAge development)
- Belsky et al., 2017 (aging measures comparison)
- Tancreda et al., 2025 (mechanistic pathways)
- Xu et al., 2025 (mitochondrial mechanisms)
- Mao et al., 2024 (inflammatory pathways)
- Niemiec et al., 2023 (developmental effects)

---

*Synthesis completed: February 13, 2026*
*Literature base: 45+ peer-reviewed articles*
*All citations verified with DOIs*
